This disclosure relates generally to medical devices, and more specifically, to inflow or outflow cannulas that may include a tissue anchor.
Cannulas may be able to create flow conduits within a patient. For example, cannulas may be used to create flow conduits to or from an organ such as the heart. A cannula may be used to create an inflow or outflow conduit from the heart. In certain instances, a cannula may be used to create an inflow conduit from the heart in cardiac assist applications to increase blood from the heart to assist with blood circulation in a patient. Arranging the cannula within an organ such as the heart may use an anchoring structure.
According to one example (“Example 1”), an inflow or outflow cannula apparatus includes a conduit having an exterior surface and an interior surface; an inlet portion arranged at a first end of the conduit including a plurality of elongate members arranged about a circumference of the inlet portion configured to deploy against a tissue wall; and a graft portion covering and arranged between the plurality of elongate members and extending along the interior surface of the conduit.
According to another example (“Example 2”), further to the apparatus of Example 1, the graft portion is arranged on an exterior surface and an interior surface of the plurality of elongate members.
According to another example (“Example 3”), further to the apparatus of any one of Examples 1-2, the graft portion is arranged along an interior surface of the plurality of elongate members and extends along the interior surface of the conduit to a second end of the conduit.
According to another example (“Example 4”), further to the apparatus of Example 3, the graft portion extends along an exterior surface of the plurality of elongate members.
According to another example (“Example 5”), further to the apparatus of any one of Examples 1-3, the inlet portion is configured to conform to the tissue wall and lessen tissue erosion thereof.
According to another example (“Example 6”), further to the apparatus of any one of Examples 1-5, the exterior surface of the conduit is configured to lessen thrombus formation.
According to another example (“Example 7”), further to the apparatus of any one of Examples 1-6, the inlet portion includes a funnel shape in an initial configuration and is configured to flatten and deploy against the tissue wall.
According to another example (“Example 8”), further to the apparatus of any one of Examples 1-7, the apparatus also includes a constraining ring arranged about the plurality of elongate members to maintain the inlet portion in a substantially cylindrical configuration and allow release of the inlet portion to flatten and deploy against the tissue wall.
According to another example (“Example 9”), further to the apparatus of Example 8, the constraining ring is configured to slide away from the first end of the conduit in response to contact with an epicardial surface of the heart to allow release of the inlet portion.
According to another example (“Example 10”), further to the apparatus of any one of Examples 1-9, the apparatus also includes a plurality of ring structures arranged along the exterior surface of an outflow portion of the conduit.
According to another example (“Example 11”), further to the apparatus of any one of Examples 1-10, the inlet portion is configured to deploy against the tissue wall in response to fluid flow pressure with a heart chamber.
According to another example (“Example 12”), further to the apparatus of any one of Examples 1-10, the conduit includes an adjustable cannula portion having a threaded surface and a stop, and the stop is configured to travel along a length of the threaded surface to adjust a position of the inlet portion relative to the tissue wall
According to one example (“Example 13”), an anchoring structure for an inflow or outflow cannula includes an inlet portion including a plurality of elongate members arranged about a circumference of the inlet portion configured to deploy against a tissue wall; an outflow portion arranged distal of the inlet portion and including an exterior surface and an interior surface; a graft portion covering and arranged between the plurality of elongate members and extending along an interior surface of the outflow portion.
According to another example (“Example 14”), further to the anchoring structure of Example 13, the inlet portion includes a funnel shape in an initial configuration and is configured to flatten and deploy against the tissue wall.
According to another example (“Example 15”), further to the anchoring structure of any one of Examples 13-14, the graft portion is arranged on an exterior surface and an interior surface of the plurality of elongate members.
According to another example (“Example 16”), further to the anchoring structure of any one of Examples 13-15, the graft portion is arranged along an interior surface of the plurality of elongate members and extends along the interior surface of the outflow portion and the graft portion extends along an exterior surface of the plurality of elongate members.
According to another example (“Example 17”), further to the anchoring structure of any one of Examples 13-16, the inlet portion is configured to deploy against the tissue wall in response to fluid flow pressure with a heart chamber.
According to one example (“Example 18”), a method of anchoring a cannula within a patient's heart includes arranging an anchoring structure in a delivery configuration, the anchoring structuring including a plurality of elongate members and graft portion covering and arranged between the plurality of elongate members; moving the anchoring structure within the heart; and allowing the anchoring structure to expand from the delivery configuration and deploy against a tissue wall.
According to another example (“Example 19”), further to the method of Example 18, the method also includes arranging a constraining ring about the plurality of elongate members to maintain the anchoring structure in a delivery configuration.
According to another example (“Example 20”), further to the method of Example 19, moving the anchoring structure within the heart slides the constraining ring from about the plurality of elongate members to allow release of the anchoring structure to flatten and deploy against the tissue wall in response to fluid flow pressure within the heart chamber.
According to another example (“Example 21”), further to the method of Example 20, moving the anchoring structure includes forcing the constraining ring against an epicardial surface of the heart to allow release of the anchoring structure.
According to another example (“Example 22”), further to the method of Example 18, the conduit includes an adjustable cannula portion having a threaded surface and a stop, and the stop is configured to travel along a length of the threaded surface, and the method also includes adjusting the stop along the threaded surface to adjust a position of the inlet portion relative to the tissue wall
According to one example (“Example 23”), a method for reducing thrombus associated with ventricular assist devices includes arranging an anchoring structure within a patient's heart, the anchoring structuring including a plurality of elongate members and graft portion covering and arranged between the plurality of elongate members; and pumping blood through the anchoring structure and through a conduit coupled to the anchoring structure.
The foregoing Examples are just that, and should not be read to limit or otherwise narrow the scope of any of the inventive concepts otherwise provided by the instant disclosure. While multiple examples are disclosed, still other embodiments will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative examples. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature rather than restrictive in nature.
The accompanying drawings are included to provide a further understanding of the disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments, and together with the description serve to explain the principles of the disclosure.
This disclosure is not meant to be read in a restrictive manner. For example, the terminology used in the application should be read broadly in the context of the meaning those in the field would attribute such terminology.
With respect to terminology of inexactitude, the terms “about” and “approximately” may be used, interchangeably, to refer to a measurement that includes the stated measurement and that also includes any measurements that are reasonably close to the stated measurement. Measurements that are reasonably close to the stated measurement deviate from the stated measurement by a reasonably small amount as understood and readily ascertained by individuals having ordinary skill in the relevant arts. Such deviations may be attributable to measurement error, differences in measurement and/or manufacturing equipment calibration, human error in reading and/or setting measurements, minor adjustments made to optimize performance and/or structural parameters in view of differences in measurements associated with other components, particular implementation scenarios, imprecise adjustment and/or manipulation of objects by a person or machine, and/or the like, for example. In the event it is determined that individuals having ordinary skill in the relevant arts would not readily ascertain values for such reasonably small differences, the terms “about” and “approximately” can be understood to mean plus or minus 10% of the stated value.
Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatuses configured to perform the intended functions. It should also be noted that the accompanying drawing figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the drawing figures should not be construed as limiting.
Various aspects of the present disclosure are directed to apparatuses, systems, and methods that may be used in improving or assisting the cardiac function of the heart. The disclosed to apparatuses, systems, and methods generally include an anchoring structure or inlet portion of a cannula that may be arranged within a patient's heart. The disclosed anchoring structure or inlet portion of a cannula may be used with a pump system for increasing blood flow in a patient.
The anchoring structure 100 also includes an outflow portion 106 arranged distal of the inlet portion 102 and including an exterior surface and an interior surface. A graft portion 108 may cover and be arranged between the plurality of elongate members 104 as is shown in
In certain instances, the graft portion 108 may also extend about a distal end of the inlet portion 102 and cover an exterior surface of the inlet portion 102. In other instances, a second graft portion or layer may extend to cover the exterior surface of the inlet portion 102. The graft portion 108 may extend between and within the spaces of the plurality of elongate members 104. In certain instances, the graft portion 108 may be configured to stretch and recover in response to forces acting on the graft portion 108. The stretching may facilitate conformability. For further discussion regarding the material properties of the graft portion 108, reference may be made to U.S. Pat. No. 4,877,661 (“House, et al.”), which is incorporated herein by reference.
As shown, the inlet portion 102 may include a funnel shape in an initial configuration. The plurality of elongate members 104 may be shape set in the funnel shape in certain instances. The inlet portion 102 may be configured to flatten and deploy against the tissue wall. In certain instances, the inlet portion 102 is configured to deploy against the tissue wall in response to fluid flow pressure with a heart chamber.
As discussed in further detail below, the anchoring structure 100 may be arranged with an outflow or inflow cannula and coupled to a pump. The anchoring structure 100 may contact the tissue wall of a patient's heart and stabilize the cannula. The anchoring structure 100 is configured to contact and conform to the tissue wall and provide an inlet for blood flow out of the heart. The anchoring structure 100 may lessen stasis and thrombus formation by maintaining contact against the tissue wall as discussed in further detail below. The plurality of elongate members 104 may stabilize the anchoring structure 100 and the graft portion 108 may cover the entirety of the plurality of elongate members 104 to lessen tissue erosion.
In addition, the patterns that form the plurality of elongate members 104 may be formed into an inlet portion or anchoring structure as shown in
In addition and as shown, the patterns include a shoulder portion 212 that the plurality of elongate members 104 extend from. The height or length may be varied as shown in comparing the patterns shown in
The cannula 320 may also include a graft portion 108 covering and arranged between the plurality of elongate members 104 and extending along the interior surface of the conduit 322. In certain instances, the graft portion 108 is arranged on an exterior surface and an interior surface of the plurality of elongate members 104. In addition, the graft portion 108 may be arranged along an interior surface of the plurality of elongate members 104 and extend along the interior surface of the conduit 322 to a second end 106 (or outflow portion) of the conduit. The graft portion 108 may also extend along an exterior surface of the plurality of elongate members 104.
The inlet portion 102 may contact the tissue wall of a patient's heart and stabilize the cannula 320. The inlet portion 102, by way of the elongate members 104 and the graft portion 108, may be configured to contact and conform to the tissue wall and provide an inlet for blood flow out of the heart. The inlet portion 102 may lessen stasis and thrombus formation by maintaining contact against the tissue wall as opposed to extending into the heart. The plurality of elongate members 104 may stabilize the anchoring structure 100 and the graft portion 108 may cover the entirety of the plurality of elongate members 104 to lessen tissue erosion.
As shown, the inlet portion 102 includes a funnel shape in an initial configuration and is configured to flatten and deploy against a tissue wall (e.g., as shown in
A plurality of ring structures 324 arranged may be along the exterior surface of an outflow portion 106 of the conduit 322. The plurality of ring structures 324 may be a biocompatible non-metallic material such as densified ePTFE. For further discussion to densified ePTFE, reference may be made to U.S. Pat. No. 5,843,171 (“Campbell et al.”) and U.S. Pat. No. 5,747,128 (“Campbell et al.”), which is incorporated herein by reference. The plurality of ring structures 324 may facilitate kink resistance and hoop strength of the outflow portion 106 of the conduit 322.
In certain instances, the graft portion 108 may include a coating that is configured to minimize a thrombogenic response that may occur due to exposure of the graft portion 108 to blood contact. In certain instances, the coating may be a heparin coating. The heparin coating is utilized to bind heparin molecules to the graft portion 108. For further discussion regarding a heparin coated graft portion 108, reference may be made to U.S. Pat. No. 6,461,665 (“Scholander”) for the specific teachings of antithrombogenic activity of surface immobilized heparin, which is incorporated herein by reference. In certain instances, the heparin coating may be CARMEDA® BioActive Surface (CBAS® Heparin Surface).
In certain instances, the heparin coating may be applied to the graft portion 108 in one or more layers. The chemical constituents of the covering material in each layer can be the same or different. In some instances, the covering material is cross-linked to itself or other covering materials in other layers. The cross-linking bonds can be covalent or ionic. The heparin covering may form at least one layer on at least a portion of the graft portion 108 and may cross-link to itself or other layers of the covering. The cross-linking can be covalent, ionic, or both. For reference regarding the application of layers of heparin to the graft portion 108, reference may be made to U.S. Pat. No. 9,399,085 (Cleek et al.), which is incorporated herein by reference.
In some instances, the graft portion 108 is configured to induce rapid tissue ingrowth therein on at least a portion of an exterior (tissue contacting) surface. In these instances, the configuration or material properties of the graft portion 108 covering the exterior surface of the inlet portion 102 may be different than properties of the interior graft portion 108. The graft portion 108 may be different layers of the same graft portion 108 or the exterior may include a different second graft portion. For ingrowth, the graft portion 108 can have a microporous structure that provides a tissue ingrowth scaffold for durable occlusion and supplemental anchoring strength of plurality of elongate members 104.
In certain instances, the cannula 320 may include a coupling section 330. The coupling section 330 may be used to seal and secure the cannula 320 with an opening created in the tissue. For example, an opening may be created in the heart (ventricle or atrium) when the cannula 320 is arranged therein. The inlet portion 102, as noted above, is arranged on an interior wall of the heart tissue (as also shown in FIG. 4). The coupling section 330 may seal the opening and hold the cannula 320 in place. In certain instances, sutures may be arranged through the coupling section 330 to secure the coupling section 330 to the heart tissue.
As shown in
In addition and as is shown, the graft portion 108 may be arranged along an interior surface of the plurality of elongate members 104 and extend along an interior surface 452 of a conduit 322 to a second end (or outflow portion) of the conduit.
The pump 200 may generally be any pump 200 that is configured to drive or otherwise cause blood to flow across the pump 200 through the cannula 320 from the inlet portion 102 to and through the outflow cannula 550. The outflow cannula 550, as shown, may include a plurality of ring structures 552 to facilitate kink resistance and hoop strength as noted above with reference to the ring structures 324 on the inflow cannula 320. The pump mechanism (also referred to herein as a pump drive) of the pump 200 may be, for example, a centrifugal-action pump, an axial-action pump, a positive displacement pump, a pulsatile pump, or other similar device such as a worm-style drive mechanism, or impeller. The pump 200 can be operated to draw blood from the left ventricle (or other heart chamber) and across the pump 200.
In certain instances, the system further includes a driveline 400. The driveline 400 is a cable assembly that operates to electrically couple a controller 500 located external to the patient's anatomy with the pump 200 or the driveline 400 can be a rotating driveshaft. The driveline 400 may be routed through the patient's vasculature and then out through the skin to where it is coupled with the controller 500 or to a subcutaneously implanted controller 500. The controller 500 is a module that is configured to control the operation of the pump 200. The controller 500 may include a battery to control operation of the pump 200. In certain instances, the controller 500 may be integrated into the pump 200 such that the system may be configured to operate without the need for the driveline 400, or the driveline 400 need not extend extracorporeally.
In addition, an extracorporeal control system may be configured to both control the operation of the pump, and to power the pump wirelessly (e.g., through a transcutaneous energy transmission system). In some examples, transcutaneous energy transmission may be accomplished through known means of transcutaneous energy transmission, such as those described in U.S. Pat. No. 6,400,991. Such a configuration eliminates the need to route the driveline 400 through the vasculature and out through a percutaneous access site, which can help minimize a risk for infection. In some examples, the pump 200 may include an “antenna” (or internal coil) that is configured for transcutaneous energy transfer (“TET”). In some examples, an extracorporeal TET component maybe worn around the torso similar to a standard heart rate monitor, and additionally coupled to a power source (wall unit or high capacity battery) such that the extracorporeal TET component is operable to transmit energy transcutaneously to the antenna.
The constraining ring 650 may be configured to slide away from the inlet end of the conduit 322 (e.g., the inlet end) in response to contact with an epicardial surface of the heart to allow release of the inlet portion.
Moving the inlet portion 102 includes forcing the constraining ring 650 against an epicardial surface of the heart to allow release of the inlet portion 102, in certain instances. The opening created in the heart tissue may be smaller than an outer diameter of the constraining ring 650 to ensure that the constraining ring 650 does not enter the heart. In certain instances, an actuator or line may be coupled to the constraining ring 650 such that a physician may manually actuate the constraining ring 650.
In certain instances, an inlet portion 102 (as discussed in detail above) may be arranged at a first end 1106 of the adjustable cannula portion 1100. A conduit 322 (as discussed in detail above) may form a portion of the adjustable cannula portion 1100 a second end 1108 of the adjustable cannula portion 1100.
In certain instances, the closer the stop 1102 is arranged to the inlet portion 102, the less the inlet portion 102 is arranged within the heart. For example and as shown in
A biocompatible material for the graft components, discussed herein, may be used. In certain instances, the graft may include a fluoropolymer, such as a polytetrafluoroethylene (PTFE) polymer or an expanded polytetrafluoroethylene (ePTFE) polymer. In some instances, the graft may be formed of, such as, but not limited to, a polyester, a silicone, a urethane, a polyethylene terephthalate, or another biocompatible polymer, or combinations thereof. In some instances, bioresorbable or bioabsorbable materials may be used, for example a bioresorbable or bioabsorbable polymer. In some instances, the graft can include Dacron, polyolefins, carboxy methylcellulose fabrics, polyurethanes, or other woven, non-woven, or film elastomers.
In addition, nitinol (NiTi) may be used as the material of the frame or stent (and any of the frames discussed herein), but other materials such as, but not limited to, stainless steel, L605 steel, polymers, MP35N steel, polymeric materials, Pyhnox, Elgiloy, or any other appropriate biocompatible material, and combinations thereof, can be used as the material of the frame. The super-elastic properties and softness of NiTi may enhance the conformability of the stent. In addition, NiTi can be shape-set into a desired shape. That is, NiTi can be shape-set so that the frame tends to self-expand into a desired shape when the frame is unconstrained, such as when the frame is deployed out from a delivery system.
In certain instances, the coating, as discussed in detail above, may include bio-active agents in addition to heparin or alternatively to heparin. The agents can include, but are not limited to, vasodilator, anti-coagulants, anti-platelet, anti-thrombogenic agents.
The invention of this application has been described above both generically and with regard to specific embodiments. It will be apparent to those skilled in the art that various modifications and variations can be made in the embodiments without departing from the scope of the disclosure. Thus, it is intended that the embodiments cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.
This application is a national phase application of PCT Application No. PCT/US2021/016532, internationally filed on Feb. 4, 2021, which claims the benefit of Provisional Application No. 62/969,824, filed Feb. 4, 2020, which is incorporated herein by reference in its entirety for all purposes.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2021/016532 | 2/4/2021 | WO |
Number | Date | Country | |
---|---|---|---|
62969824 | Feb 2020 | US |